4,665 Incident Cases of Meningococcal Disease were Registered in the 8MM, Says GlobalData27 May 2013 • by Natalie Aster
Meningococcal disease is caused by Neisseria meningitidis, which is an encapsulated, Gram-negative bacterium that has an incidence of one to three cases per 100,000 population worldwide (Giuliani et al., 2006). Strains of Neisseria meningitidis are classified based on the chemical composition of unique polysaccharide capsules. Although there are 13 different serogroups, nearly all disease in humans is caused by strains representative of six serogroups: A, B, C, W-135, X and Y (CDC, 2012d; Halperin et al., 2012; Rosenstein et al., 2001). Humans are the only natural reservoir of Neisseria meningitidis, and the bacterium causes three common clinical forms of meningococcal disease: meningitis, blood infection, and pneumonia (CDC, 2012d; Wilder-Smith and Memish, 2003). Up to 10% of adolescents and adults are asymptomatic, transient carriers of the bacterium, which can be transmitted via respiratory droplets or by direct contact (CDC, 2012d).
New report “EpiCast Report: Meningococcal Disease - Epidemiology Forecast to 2022” by GlobalData provides an overview of the risk factors and global trends for meningococcal disease in eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Australia, and Brazil). It includes a 10-year epidemiological forecast of incident cases of meningococcal disease segmented by age (<1, 1–4, 5–14, 15–24, 25–44, 45–64, and 65 years) and serogroup (B, C, Y, and W-135) in these markets. The other serogroups, namely serogroups A and X, are not covered in this analysis because they have very low prevalence in the 8MM and because little data are available for these serogroups. Germany is the only country that had data available for serogroup A, and therefore serogroup A is included in this analysis for Germany. Due to the low incidence of meningococcal disease in Japan, this market was not included in the forecast.
EpiCast Report: Meningococcal Disease - Epidemiology Forecast to 2022
Published: May, 2013
Price: US$ 3,995.00
In 2012, there were 4,665 incident cases of meningococcal disease in the 8MM, and by 2022 GlobalData epidemiologists estimate there will be 4,784 incident cases (Annual Growth Rate [AGR]: 0.26%). The US will have the highest AGR at 1.19%, and Germany will have the lowest at negative 0.39%. Although Spain will have a low AGR of 0.01%, by 2022 the market will have the second highest number of incident cases of meningococcal disease (968 incident cases) in the 8MM, following the UK (1,219 incident cases).
During the forecast period, the number of incident cases will remain relatively stable. An increase in international travel to regions of high incidence could cause some serogroups to appear in countries where they were not previously prevalent. In addition to vaccinating international travelers, the vaccination of household members of individuals traveling to high-risk regions would further prevent outbreaks due to strains that certain populations are not yet immune to.
More information can be found in the report “EpiCast Report: Meningococcal Disease - Epidemiology Forecast to 2022” by GlobalData.
To order the report or ask for sample pages contact firstname.lastname@example.org